Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetes Phase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical compan

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult patients with unresectable or metastatic HER2-positive breast cancer. The approval follows previous Priority Review and Breakthrough Therapy designations from the FDA. It is based on data from the phase 3 DESTINY-Breast09 trial, which enrolled 1,157 patients across multiple sites in Europe, the US, Asia, Africa and South America. The trial found that Enhertu in combination wit

iStock, RomoloTavani These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech. 2025 proved to be a high-drama year for dealmaking as pharmas fought over companies, swallowed their rivals and found inspiration in other companies’ transactions. The biggest deal of the year—Johnson & Johnson’s $14.6 billi

iStock, XtockImages Biotech’s slump may finally be over in 2026. In interviews with BioSpace , Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback. As the pharma and biotech industry head into the J.P. Morgan Healthcare Conference 2026 in January on firmer footing, several forces are nurturing the landscape’s cautious optimism: the resurgence of deals and partnerships, successful alternative financing models and China’s accelerating role

PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free standard of care in an earlier stage of bladder cancer Results from the Phase 3 EV-304 trial will be p

iStock, hapabapa BMS is Harbour’s second powerhouse partner this year after the Chinese biotech signed a potential $4.68 billion deal with AstraZeneca in March. Bristol Myers Squibb is betting more than $1 billion for Harbour BioMed’s multi-specific antibodies, continuing the trend of Big Pharma turning to China for innovation. Under the terms of the agreement, announced Tuesday , BMS will pay $90 million upfront to collaborate with the Chinese biotech on developing and advancing multi-specifi

iStock, SvetaZi Roche CEO Thomas Schinecker said during the company’s Q3 call that it is “not done” with deals—a promise he delivered on with Tuesday’s solid tumor pact with AI-focused Caris Life Sciences. Roche is “not done” with deals, CEO Thomas Schinecker said during the company’s third-quarter earnings call in October. The pharma bore that out on Tuesday as its subsidiary Genentech partnered with AI-focused Caris Life Sciences to advance novel therapies for solid tumors. Under the term

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical d

Scientists at Northern Arizona University are developing a promising new way to detect Alzheimer’s disease earlier than ever before—by tracking how the brain uses sugar. Using tiny particles in the blood called microvesicles, researchers may soon be able to gather brain-specific information without invasive procedures. If successful, this approach could transform Alzheimer’s diagnosis, monitoring, and even prevention, much like how doctors manage heart disease today.Researchers at Northern Arizo

Medicus Pharma has announced the completion of patient enrollment for its phase 2 SKNJCT-003 trial, evaluating the safety and efficacy of SkinJect Doxorubicin Microneedle Array (D-MNA) in the treatment of nodular basal cell carcinoma (BCC) of the skin. The study is currently underway in nine clinical sites across the US, and has recruited a total of 90 US patients. Medicus expects to release topline study results in early 2026, and to secure an end-of-phase 2 (EOP2) meeting with the US FDA in th